Indeed, immunotherapeutic strategies which are used in the clinic either (i) bypass MHC I presentation (e.g., chimeric antigen receptor, CAR-T cell therapy) or (ii) skip the step of cancer-specific MAPs identification because they rely on a pre-existing antitumoral T cell response (e.g., ICI therapies). This evidence concerns the gene C3orf62 and cancer.